DALLAS--Today, the national law firm of Baron & Budd announced that it is accepting cases on...READ MORE
Baron and Budd Named to Inaugural America’s Elite Trial Lawyers List by The National Law Journal
Prestigious List Selects 50 Prestigious Law Firms That are Doing the Most Substantial, Influential Work on Behalf of Plaintiffs
DALLAS (September 22, 2014) – This week, the law firm of Baron and Budd was named to America’s Elite Trial Lawyers by legal publication The National Law Journal in partnership with Law.com. The list is comprised of just 50 law firms from across the nation that have achieved significant, groundbreaking results on behalf of plaintiffs within the past year and have an established track record of delivering impressive results.
Firms selected to the list have exhibited cutting edge work on behalf of plaintiffs in the United States. According to the publication, competition was very fierce.
“We could not be more proud of the fact that we have been included in this inaugural list,” said Russell Budd, co-founder and managing shareholder of the national law firm of Baron and Budd. “Being selected to this list is a testament to how hard our attorneys work for clients every day.”
The National Law Journal will release more information on each of the winners on Sept. 29.
These are just some of the significant results Baron and Budd achieved that warranted inclusion on the list:
[checklist icon=”fa-angle-right” iconcolor=”#222″ circle=”no” id=”ls”]
- Baron and Budd represented Kentucky, Maryland, Mississippi, New Mexico, South Carolina, Utah and West Virginia in litigation involving the fraudulent marketing of Avandia, a popular diabetes drug, by manufacturer GlaxoSmithKline. The resulting $177 million settlement is the largest ever regarding a pharmaceutical lawsuit for several of the states involved in the case. These states chose to opt-out of the 2012 multistate Avandia settlement. As a result, each state received a significantly higher settlement than what they would have otherwise.
- The firm took a leadership role in achieving more than $33 million in settlements on behalf of the States of Mississippi, Hawaii and West Virginia in lawsuits over deceptive credit card payment protection plans. Though many consumers have been approached by their credit card companies to sign up for a payment protection program, these phone calls are often misleading and frequently lead consumers to sign up unknowingly for a payment protection program. Once signed up, consumers are charged monthly fees for their participation in the service, though the plan offers no real benefit for consumers and is only a way for the credit card company to make additional profit.
- Baron and Budd served as lead counsel in a confidential settlement on behalf of the City of Wasco, California regarding contamination of local well water by TCP. After five years of litigation with Dow Chemical and Shell, the firm’s attorneys reached a settlement with the two companies that will provide the City of Wasco with funds to help remove TCP from contaminated water.
- Baron and Budd took the lead in a lawsuit involving faulty transmissions in BMW’s popular Mini Coopers. The case resulted in a major national settlement that was valued at more than $10 million and will allow Mini Cooper owners to receive individual compensation for their transmission problems.
About Baron & Budd, P.C.
The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with almost four decades of experience “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as PCB contamination in schools, FLSA (overtime) violations, pharmaceutical and medical implant injuries, water contamination, GM ignition problems, California Proposition 65 violations, mortgage and credit card fraud and asbestos-related illnesses such as mesothelioma.